Is There a Generic for Atzumi?

No. The Orange Book lists no active FDA-approved generic (ANDA) for Atzumi (dihydroergotamine). The Orange Book shows its last listed patent expires October 12, 2041 and its last listed exclusivity ends April 30, 2028.

Run it in Rivvi

Map Atzumi and your other top fills to their generics

Every strength in RxNorm, with brands that have no generic flagged.

Build the map

Free to start. Opens Rivvi, the AI workspace for healthcare teams.

Atzumi products in the Orange Book

Atzumi products and approved generics
Form and route	Strength	Brand status	Brand TE	Active generics	Generic TE codes
powder, nasal	EQ 5.2MG BASE	Marketed (Rx)	None	0	None

NDA 217901, held by SATSUMA PHARMACEUTICALS INC. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.

Atzumi patents

Patents listed for Atzumi
Patent	Expires	Covers	Use code	NDA
12594273	September 24, 2033	Drug product	None	217901
11872314	August 4, 2037	Drug product	None	217901
10792253	August 4, 2037	Drug product	None	217901
10758532	December 11, 2039	Drug product	None	217901
12263162	December 11, 2039	Drug product	None	217901
12102754	October 12, 2041	Drug product	None	217901
11744967	October 12, 2041	Drug product	None	217901

Atzumi exclusivity

Exclusivity listed for Atzumi
Code	Meaning	Expires	NDA
NP	New product	April 30, 2028	217901

Atzumi NDC codes

76978-101

Questions

Is there a generic for Atzumi?

No. The Orange Book lists no active FDA-approved generic (ANDA) for Atzumi (dihydroergotamine). The Orange Book shows its last listed patent expires October 12, 2041 and its last listed exclusivity ends April 30, 2028.

What is the generic name for Atzumi?

The active ingredient in Atzumi is dihydroergotamine, per the FDA Orange Book.

When does the Atzumi patent expire?

The last patent listed for Atzumi in the Orange Book expires October 12, 2041. A listed patent expiry date is not a generic launch date.

What does a therapeutic equivalence code mean?

In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.